WO2023034313A1 - Implant d'allogreffe préformé destiné à être utilisé en chirurgie reconstructrive et procédés de fabrication et d'utilisation, et outils pour former un tel implant - Google Patents
Implant d'allogreffe préformé destiné à être utilisé en chirurgie reconstructrive et procédés de fabrication et d'utilisation, et outils pour former un tel implant Download PDFInfo
- Publication number
- WO2023034313A1 WO2023034313A1 PCT/US2022/042058 US2022042058W WO2023034313A1 WO 2023034313 A1 WO2023034313 A1 WO 2023034313A1 US 2022042058 W US2022042058 W US 2022042058W WO 2023034313 A1 WO2023034313 A1 WO 2023034313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adm
- graft
- shape
- domed
- shaped
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 46
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000007943 implant Substances 0.000 title claims description 9
- 230000002500 effect on skin Effects 0.000 claims abstract description 26
- 238000007493 shaping process Methods 0.000 claims abstract description 18
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- 210000001519 tissue Anatomy 0.000 claims description 39
- 210000003491 skin Anatomy 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 19
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 238000004659 sterilization and disinfection Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 15
- 238000004806 packaging method and process Methods 0.000 claims description 15
- 230000036512 infertility Effects 0.000 claims description 9
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 238000012079 reconstructive surgical procedure Methods 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 description 24
- 238000001356 surgical procedure Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010040102 Seroma Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002278 reconstructive surgery Methods 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000282979 Alces alces Species 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- An allograft includes bone, tendon, skin, or other types of tissue that is transplanted from one person to another. Allografts are used in a variety of medical treatments, such as knee replacements, bone grafts, spinal fusions, eye surgery, and skin grafts for reconstructive surgery and for the severely burned. Allografts come from voluntarily donated human tissue obtained from cadaveric donor-derived, living-related, or living-unrelated donors and can help patients regain mobility, restore function, enjoy a better quality of life, and even save lives in the case of cardiovascular tissue or skin.
- An acellular dermal matrix (ADM) graft is a soft connective tissue graft generated by a decellularization process that preserves the intact extracellular skin matrix. Upon implantation, the ADM structure serves as a scaffold for donorside cells to facilitate subsequent incorporation and revascularization.
- ADMs are manufactured utilizing known methods of decellularization by means of ionic and nonionic detergent methods, as well as those utilizing enzymatic processes and other techniques such as those listed in “Decellularization of Tissues and Organs,” Gilbert, et al, 2006 (https://www.ncbi.nlm.nih.gov/pubmed/16519932).
- ADM grafts are primarily derived from decellularized cadaveric skin and must be shaped and/or cut as necessary by the surgeon either prior to or during a surgical procedure. Such grafts are also commonly formed from solid or perforated ADM. As a result, existing ADM grafts present efficiency, efficacy, and repeatability challenges when used for reconstructive surgery purposes. Summary
- One embodiment provides a method of manufacturing an acellular dermal matrix (ADM) graft product for use in a reconstructive surgical procedure.
- the method may include the following steps: (1) providing a portion of donor- derived skin, the portion of the donor-derived skin having a full thickness; (2) removing an epidermis layer and a fat layer from the portion of the donor-derived skin to form a portion of dermal tissue; (3) decellularizing the portion of the dermal tissue to form a portion of ADM graft material; (4) forming the portion of the ADM graft material into a pre-defined shape in anticipation of the reconstructive surgical procedure; (5) fenestrating the pre-defined shape into a mesh pattern; (6) verifying that a thickness of the pre-defined shape equals a specified thickness; (7) packaging the pre-defined shape in a medical sterilization pouch to form a packaged, pre-shaped, and meshed ADM graft; and (8) irradiating the packaged, pre-shaped, and meshed ADM graft
- Another embodiment provides a pre-shaped, meshed acellular dermal matrix (ADM) graft stored as a packaged graft product prepared by a process comprising the steps of: (1) providing a portion of ADM tissue having a thickness between 1 mm and 2 mm; (2) fenestrating the portion of the ADM tissue in a mesh pattern extending over an entirety of the portion of the ADM tissue; (3) scoring the portion of the ADM tissue into a pre-defined shape to form the pre-shaped, meshed ADM graft; (4) verifying the thickness of the pre-shaped, meshed ADM graft; (5) packaging the pre-shaped, meshed ADM graft in a medical sterilization pouch; and (6) irradiating the pre-shaped, meshed ADM graft within the medical sterilization pouch to a sterility assurance level of 10' 6 to form the packaged graft product.
- ADM acellular dermal matrix
- ADM graft product may include an ADM graft derived from fullthickness skin, the ADM graft having a pre-formed shape with a mesh pattern formed therein, as well as a medical sterilization pouch sealed about the ADM graft, wherein when the medical sterilization pouch and the ADM graft are irradiated to a sterility assurance level of 10' 6 , the ADM graft product has a shelflife of two years.
- a method of manufacturing an acellular dermal matrix (ADM) graft product for use in a reconstructive surgical procedure may include providing a portion of donor-derived skin, the portion of the donor-derived skin having a full thickness.
- the method may include removing an epidermis layer and a fat layer from the portion of the donor-derived skin to form a portion of dermal tissue.
- the method may include decellularizing the portion of the dermal tissue to form a portion of ADM graft material.
- the method may include forming the portion of the ADM graft material into a pre-defined shape in anticipation of the reconstructive surgical procedure, and the forming the portion of the ADM graft material into the predefined shape comprises at least one of scoring and cutting the portion of the ADM graft material into a domed shape ADM graft.
- the method may include verifying that a thickness of the pre-defined shape equals a specified thickness.
- the method may include packaging the domed shape ADM graft in a medical sterilization pouch to form a packaged and domed shape ADM graft.
- the method may include irradiating the packaged and domed shaped ADM graft to a sterility assurance level of 10' 6 to form the ADM graft product.
- a domed shaped acellular dermal matrix (ADM) graft stored as a packaged graft product prepared by a process.
- the process may include a step of providing a portion of ADM tissue having a thickness between 1 mm and 2 mm.
- the process may include a step of scoring the portion of the ADM tissue into a pre-defined shape to form the domed shape ADM graft.
- the process may include a step of verifying the thickness of the domed shape ADM graft.
- the process may include a step of packaging the domed shaped ADM graft in a medical sterilization pouch.
- the process may include a step of irradiating the domed shaped ADM graft within the medical sterilization pouch to a sterility assurance level of 10' 6 to form the packaged graft product.
- a tool or set of tools having a set of features for forming a domed ADM graft.
- the set of features may include a shaping tool feature having a shaping portion configured to shape a dome shaped ADM graft.
- the set of features may include a scoring tool feature having a scoring portion configured to impart a desired mesh pattern into the domed shaped ADM graft.
- ADM graft that combines the ADM as designed with antimicrobial elements that mitigate or prevent complications arising from post-surgical infections.
- Antimicrobial agents that are compatible with the ADM include silver in its colloidal, elemental or ionic form. The silver may be complexed with chelating agents or may be added directly to the ADM prior to final packaging. Similarly other antimicrobial agents may be combined with the ADM.
- Other agents well known to be used medically are chlorhexidine gluconate and antimicrobial peptides of various amino acid chain length.
- FIGURES 1A-1 B illustrate respective front-plan and perspective views of one embodiment of a pre-shaped, meshed acellular dermal matrix (ADM) graft derived from full-thickness skin;
- ADM acellular dermal matrix
- FIGURES 2A-2B illustrate respective top-perspective and bottomperspective views of one embodiment of scoring tool for manufacturing the preshaped, meshed ADM graft of FIGURES 1 A-1 B;
- FIGURES 3A-3B illustrate front-plan views of an exemplary mesh, or fenestration, pattern of the pre-shaped, meshed ADM graft of FIGURES 1A-1B, shown in an open position and in a resting position, respectively;
- FIGURE 4 illustrates a perspective view of an exemplary skin mesher for forming the mesh pattern of FIGURES 3A-3B;
- FIGURE 5 illustrates a first perforated prior art ADM graft for comparison to the pre-shaped, meshed ADM graft of FIGURES 1 A-1 B;
- FIGURE 6 illustrates a second perforated prior art ADM graft for comparison to the pre-shaped, meshed ADM graft of FIGURES 1 A-1 B;
- FIGURES 7A-7B illustrate perspective views of a fluid egress testing device in respective first and second stages of fluid egress testing of the preshaped, meshed ADM graft of FIGURES 1A-1 B, the first perforated ADM graft of FIGURE 5, and the second perforated ADM graft of FIGURE 6;
- FIGURES 8A-8B provide a table reflecting multiple sets of drainage time measurements captured during the fluid egress testing performed using the testing device of FIGURES 7A-7B;
- FIGURE 9 provides a summary graft of the drainage time measurements shown in FIGURES 8A-8B;
- FIGURE 10 illustrates a front perspective view of an ADM graft pocket formed by joining two of the pre-shaped, meshed ADM grafts of FIGURES 1A-1 B together;
- FIGURE 11 illustrates a front view of a pre-shaped, meshed ADM graft product in which the pre-shaped, meshed ADM graft of FIGURES 1A-2A is packaged for storage in a sealed medical sterilization pouch;
- FIGURE 12 illustrates the pre-shaped, meshed ADM graft product of FIGURE 11 further packaged in a medical peel pouch;
- FIGURE 13 provides a flowchart depicting an exemplary method of manufacturing an embodiment of the pre-shaped, meshed ADM graft of FIGURES 1A-1 B and the packaged ADM graft product of FIGURES 11-12;
- FIGURE 14 is a photograph of an embodiment of a domed shaped ADM graft product
- FIGURES 15A and 15B illustrate an embodiment of a shaping and scoring tool for manufacturing of the domed shaped ADM graft product of FIGURE 15;
- FIGURE 16 illustrates an alternative embodiment of a domed shaped ADM graft product having a multi-notched peripheral edge.
- a pre-shaped, meshed or fenestrated acellular dermal matrix (ADM) graft derived from full-thickness human, donor-derived skin for use in the surgical reconstruction of soft tissue defects resulting from trauma, disease, or surgical intervention.
- ADM acellular dermal matrix
- embodiments of the ADM graft discussed herein may be used in the surgical specialty of plastic surgery, and particularly in prepectoral and post-mastectomy breast reconstruction, where the ADM graft is an adjunct to integumental repair of the surgical site.
- Embodiments of the ADM graft may be packaged and irradiated for long-term sterile storage in a manner that allows them to be used in surgical procedures within two years of packaging.
- embodiments of the preshaped, meshed ADM graft provide the surgeon with a mechanism to restore function to and support integumental tissue after surgical intervention in a manner that is repeatable, effective, and time efficient by leveraging a manufactured, preshaped and meshed ADM graft product that is derived from full-thickness skin.
- Embodiments of the ADM graft facilitate fluid drainage from the surgical site to discourage seroma formation, increase the rate of integration of the ADM graft with the body, and provide a reliable, repeatable solution the surgeon may use “off the shelf’ rather than utilizing valuable time and resources for graft processing in preparation for or during the surgical procedure.
- FIGS. 1A-1 B illustrate respective front-plan and perspective views of one embodiment of a pre-shaped, meshed ADM graft 100 derived from decellularized, full-thickness skin.
- full-thickness skin as the source for the ADM graft 100 ensures that the ADM graft 100 has sufficient biomechanical properties to support varying surgical requirements, including, for example, a suitable ultimate tensile strength, suture pull-out resistance, and a Young’s modulus indicative of a soft and supple graft.
- the pre-shaped, meshed ADM graft 100 may have a pre-formed shape approximating a circle with a portion of the top removed (i.e., slightly larger than a semi-circle).
- the pre-shaped ADM graft may form a generally semi-circular tissue portion 102 having a radius, r, of 9 cm.
- the semi-circular tissue portion 102 may approximate a circle having a top portion of the circle removed in a straight line disposed perpendicular to the radius, r, of the circle.
- the tissue portion 102 may have a total height, h, of 10 cm, and a material thickness, t, of 1.0-2.0 mm.
- Additional pre- shaped ADM graft embodiments may feature various circular or elliptical shapes with diameters ranging from 10 cm to 22 cm.
- the circular or elliptical tissue portion of the ADM graft may feature a removed top portion, as shown in FIGS. 1A-1 B, or an in-tact top portion, as necessary or desired for the intended surgical preparation.
- the pre-shaped, meshed ADM graft 100 may include a notch 104 to indicate which surface provides a basement membrane surface 106, or the dermal surface to be implanted towards the patient’s vascular bed.
- the notch 104 of the graft 100 may be disposed in the top left corner to indicate the basement membrane surface 106.
- the basement membrane may be removed.
- the decellularized, full-thickness dermal tissue may be shaped and cut into the pre-shaped ADM graft 100 using an appropriately designed scoring tool along with a cutting tool such as, for example, a surgical scalpel or a surgical scissor.
- FIGS. 2A-2B illustrate respective front and rear perspective views of one embodiment of a scoring tool 130 featuring a semi-circular edge pattern 132 that incorporates a raised notch 134 configured to form the indicator notch 104 in the pre-shaped ADM graft 100.
- an embodiment of the scoring tool 130 may be placed upon a portion of full-thickness dermal tissue and used to “stamp” out the notched, semi-circular tissue portion 102 from a larger ADM tissue portion.
- the cutting tool (not shown) may be used to trim excess tissue from around a perimeter of the scoring tool 130.
- the pre-shaped nature of the ADM graft 100 disclosed herein saves the surgeon valuable time during a surgical procedure because there is no (or minimal) need for the surgeon to shape, cut, or otherwise form the ADM graft into a desired shape during surgical preparation. Instead, the surgeon may simply select an appropriately pre-shaped ADM graft for the particular surgery and proceed.
- Embodiments of the pre-shaped ADM graft 100 may additionally include a mesh or fenestration pattern to allow for increased fluid flow through the graft 100, thereby reducing the chances of post-surgical seroma formation, a frequent complication after surgeries using existing ADM grafts. Pre-meshing also prevents the surgeon from having to perform any type or kind of meshing procedures during surgical preparation or during a surgical procedure and ensures an optimal mesh ratio to provide maximum fluid egress, or drainage, from the surgical site to prevent seroma formation and a maximum graft surface area for improved integration into the body post procedure.
- FIGS. 3A-3B illustrate respective front views of an exemplary mesh, or fenestration, pattern 108 applied to the pre-shaped, meshed ADM graft 100, shown in an open position, A, in which the mesh pattern appears as a series of holes 110 (FIG. 3A) and in a resting position, B, in which the mesh pattern 108 appears as a series of straight slits or lines 112 (FIG. 3B).
- the mesh pattern 108 may feature a 1 :1 graftspace ratio in which each mesh hole 110/line 112 has a length, L, of 1 .5 mm, an end-to-end offset, Eo, of 1 .5 mm, and a lateral offset, Lo, of 1 mm.
- Alternative embodiments may feature a different mesh ratio and/or any appropriate and/or desired material and line dimensions.
- the mesh pattern 108 may feature a 2:1 graftspace ratio, with a material thickness of 0.8-2.5 mm.
- the mesh or fenestration pattern 108 may be formed in the pre-shaped, meshed ADM graft 100 using a standard “skin mesher” 140 such as, for example, a 4MED (or Rosenberg) Skin Graft Mesher (Distributed by Exsurco Medical, Wakeman, Ohio). As shown in FIG. 4, a portion of decellularized, full-thickness dermal tissue 101 or, alternatively, a pre-shaped semi-circular tissue portion 102 may be inserted into the skin mesher 140, which has been adjusted to the appropriate mesh or fenestration settings, for application of the mesh pattern 108 to the tissue 101 .
- skin mesher 140 such as, for example, a 4MED (or Rosenberg) Skin Graft Mesher (Distributed by Exsurco Medical, Wakeman, Ohio).
- a portion of decellularized, full-thickness dermal tissue 101 or, alternatively, a pre-shaped semi-circular tissue portion 102 may be inserted into the skin mesher 140, which has been adjusted to the appropriate
- a fluid egress study was completed to exhibit the increased fluid egress, or drainage, properties of the pre-shaped, meshed ADM graft 100.
- the fluid drainage properties of the pre-shaped, meshed ADM graft 100 were compared to those of a prior art first perforated ADM graft 142, shown in FIG. 5, having a first perforation density pattern 144 of 41 perforations per 320 cm 2 , or approximately .128 perforations per cm 2 , and a prior art second perforated ADM graft 146, shown in FIG.
- FIGS. 7A-7B illustrate perspective views of a fluid egress testing device 150 in first and second stages of egress testing, respectively.
- a fluid 152 was passed from a fluid column 158, through the respective tested ADM graft (i.e., the pre-shaped meshed ADM graft 100, the first perforated ADM graft 142, or the second perforated ADM graft 144) stretched across the fluid column 158 (not shown) and into a waste container 157.
- An egress or drainagetime measurement was taken of the time required for a top surface 159 the fluid 152 to fall 8.5 inches from a first fluid-level line 154 to a second fluid-level line 156 along the fluid column 158 of the fluid egress testing device 150, as shown in FIGS. 7A-7B, respectively.
- the drainage time for the fluid surface 159 to pass from the first line 154 to the second line 156 was measured in triplicate for each of the pre-shaped meshed ADM graft 100, the first perforated ADM graft 142, and the second perforated ADM graft 146.
- the drainage time measurements are provided in the table of FIGS. 8A-8B. As summarized in the chart of FIG.
- the fluid egress study showed that the pre-shaped, meshed ADM graft 100 having the 1 :1 graftspace ratio demonstrated significantly improved fluid egress properties, namely approximately 3x and 5x faster fluid egress as compared to the first and the second perforation density patterns 144, 148 of the first and the second perforated grafts 142, 146, respectively.
- the mesh pattern 108 also increases the surface area of the pre-shaped, meshed ADM graft 100, which, in turn, abets a rate of integration of the graft 100 during the healing process after surgical intervention.
- the surface area calculations below compare the pre-shaped, meshed ADM graft 100 with the first and the second perforated grafts 142, 146 having the first and the second perforation patterns 144, 148, respectively, discussed above in relation to FIGS. 5-6.
- the surface area of a 2x2 cm 2 meshed ADM graft having a 1 mm thickness and 130, 1.5 mm long mesh lines provides a 97.5% increase in surface area over a 2x2 cm 2 solid, non-meshed ADM graft, as shown below:
- the first perforated graft 142 having a 16 cm x 20 cm perimeter and a 1 mm thickness, with a perforation density pattern 144 of 41 perforations per a 320 cm 2 area, each perforation having a .15 cm radius, provides only a .3% surfacearea increase over a 16 cm x 20 cm solid, non-meshed ADM graft, as shown below:
- the second perforated graft 146 having a 16 cm x 20 cm perimeter and a 1 mm thickness, with a perforation density pattern 148 of 80 perforations per a 320 cm 2 area, each perforation having a .15 cm radius, provides only a .59% surface-area increase over a 16 cm x 20 cm solid, non-meshed ADM graft, as shown below: [0047]
- the fenestration pattern 108 applied to the pre-shaped, meshed ADM graft 100 significantly increases the exposed surface area of the graft over both existing solid and perforated grafts. This increase causes the pre-shaped, meshed ADM graft 100 to integrate into the human body much more rapidly during the healing process after surgical intervention.
- the pre-shaped, meshed ADM graft 100 may be formed of the ADM derived from full-thickness skin, as discussed above, combined with antimicrobial elements that mitigate or prevent complications arising from post-surgical infections.
- Antimicrobial agents compatible with the ADM may include, for example, silver in its colloidal, elemental, or ionic form. The silver may be complexed with chelating agents or may be added directly to the ADM prior to final packaging. Similarly, other antimicrobial agents may be combined with the ADM.
- Other agents known to be used medically may include chlorhexidine gluconate and antimicrobial peptides having various amino acid chain lengths.
- two pre-shaped, meshed ADM grafts 100 may be sutured together to form an ADM graft pocket 160.
- the two pre-shaped, meshed ADM grafts 100 may be sutured together around the curved portions each of the semi-circular tissue portions 102, such that a breast implant 162 may be disposed within the ADM graft pocket 160 between the two pre-shaped, meshed ADM grafts 100.
- the implant 162 is thus supported from the bottom, without the need to be covered at the top.
- the ADM graft pocket 160 may be pre-sutured and then packaged and stored for later surgical use, as discussed below in relation to FIGS.
- the ADM graft pocket may be formed from two pre-shaped, meshed ADM grafts 100 and sutured by the surgeon prior to or during a surgical procedure.
- the implant may be wrapped in the pre-shaped, meshed ADM graft 100 from an anterior side, and the graft 100 sutured to the chest wall.
- the pre-shaped, meshed ADM graft 100 may be packaged along with two opposing pieces of backing material 172 and sterile water in a sealed medical sterilization pouch 174 such as, for example, a Kapak pouch (manufactured by AMPAK Technology Inc. of Larchmont, NY), as shown in FIG. 11 , or further into a sealed, peelable medical sterilization pouch 176 known as a “peel pouch” or a “chevron pouch,” as shown in FIG. 12.
- a sealed medical sterilization pouch 174 such as, for example, a Kapak pouch (manufactured by AMPAK Technology Inc. of Larchmont, NY), as shown in FIG. 11 , or further into a sealed, peelable medical sterilization pouch 176 known as a “peel pouch” or a “chevron pouch,” as shown in FIG. 12.
- the packaged ADM graft product 170 may then be irradiated to a sterility assurance level (SAL) of 10' 6 such that it may be stored at room temperature for up to two years.
- SAL sterility assurance level
- the packaged ADM graft product 170 may be labeled in any appropriate manner and may include information pertaining to the raw material, the shape, a use by date, special requirements, results of a visual inspection, and so on.
- FIG. 13 provides a flowchart depicting an exemplary method (200) of manufacturing an embodiment of the pre-shaped, meshed ADM graft 100, the ADM graft pocket 160, and the packaged ADM graft product 170, discussed above.
- the method may initiate with providing a portion of fullthickness donor-derived skin (202).
- the epidermis layer and the fat layer adjacent to the dermis may be removed (204), and the dermal tissue may be decellularized according to a well-known or a proprietary decellularization process, resulting in the Acellular Dermal Matrix (ADM) (206).
- ADM Acellular Dermal Matrix
- the ADM may then be shaped and/or cut into a pre-defined shape, such as the semi-circular tissue portion 102 or another appropriate shape, as necessary for an associated or pre- determined/assigned surgical procedure (208).
- the shaping may be accomplished using any appropriate scoring tool 130 or another appropriate shaping tool, and the graft may be cut out with the cutting tool.
- the ADM may also be meshed/fenestrated in the desired mesh pattern (e.g., 1 :1 graft:space ratio, 2:1 graft:space ratio) using any appropriate skin mesher 140 (210).
- the meshing or fenestrating process (210) may occur before or after the ADM is shaped into the pre-defined shape.
- the resulting pre-shaped, meshed ADM graft 100 may then be verified for its thickness to specification (e.g., 1 mm - 2 mm) (212) using a thickness gauge, and one or more antimicrobial agents may be added to the pre-shaped, meshed ADM graft 100 to aid in post- surgical infection prevention (213).
- the graft 100 may then be packaged (214) between opposing pieces of backing material 172 within sterile water inside a selfsealing medical sterilization pouch 174 and/or a peelable pouch 176 such as, for example, a Kapak peel-pouch, forming the pre-shaped, meshed ADM graft product 170.
- the packaged ADM graft product 170 may be irradiated to SAL 10' 6 (216). After irradiation (216), the packaged, pre-shaped, meshed ADM graft product 170 may be stored up to two years (218) before it is used in a surgical procedure (220).
- two of the pre-shaped, meshed ADM grafts 100 may be joined (e.g., sutured) together about a curving portion of each individual graft 100 to form the ADM graft pocket 160 (222), discussed above in relation to FIG. 10.
- the ADM graft pocket 160 may be formed prior to a surgical procedure, within or prior to entering the operating theater.
- the method of manufacturing the packaged, pre-shaped, meshed ADM graft product 170 provides a repeatable process for manufacturing the preshaped, meshed ADM graft 100 formed from full-thickness donor-derived skin such that surgeons may rely on the time-saving graft product in reconstructive surgical procedures to provide a graft solution that has the robust physical properties required of surgical skin grafts (as opposed to burn skin grafts), promotes healing in the form of effective drainage from the surgical site, and promotes integration of the graft into the patient’s body.
- FIGS. 15A and 15B illustrate an embodiment of a shaping and scoring tool 400 for manufacturing of the domed shaped ADM graft product 300 as illustrated FIGURE 15.
- the shaping and scoring tool 400 of FIG. 15, or a similar type of device or devices, may be provided with a shaping portion 405 to impart the dome shape 305 to the ADM graft product 300.
- a scoring portion 410 integrated in the same device 305, or provided separately, is configured to impart a desired mesh pattern 310 (which may be a concentric pattern formed on edges 315 of the ADM graft product 300, or another desired mesh pattern, in addition to mesh patten 320, across an entire surface of the ADM graft 300, or the domed shaped ADM graft 300may be shaped without a mesh pattern in a specific region or without any mesh pattern across the entire ADM graft 300.)
- a desired mesh pattern 310 which may be a concentric pattern formed on edges 315 of the ADM graft product 300, or another desired mesh pattern, in addition to mesh patten 320, across an entire surface of the ADM graft 300, or the domed shaped ADM graft 300may be shaped without a mesh pattern in a specific region or without any mesh pattern across the entire ADM graft 300.
- FIG. 16 there is shown another embodiment 500 of an initial portion 325 of a domed shaped ADM graft product 300 having a multinotched peripheral edge 505.
- This multi-notched embodiment 500 may be one or both of shaped and/or scored using the shaping and scoring tool 400 of FIG. 15 or other suitable apparatus and processing steps.
- the decellularized, full-thickness dermal tissue 500 may be shaped and cut into the domed shaped ADM graft 300 using an appropriately designed scoring tool along with a cutting tool such as, for example, a surgical scalpel or a surgical scissor.
- the pre-shaped nature of the domed shaped ADM graft disclosed herein saves the surgeon valuable time during a surgical procedure because there is no (or minimal) need for the surgeon to shape, cut, or otherwise form the ADM graft into a desired shape during surgical preparation. Instead, the surgeon may simply select an appropriately pre-shaped ADM graft for the particular surgery and proceed.
- Embodiments of domed shaped ADM graft may additionally include a mesh or fenestration pattern to allow for increased fluid flow through the graft, thereby reducing the chances of post-surgical seroma formation, a frequent complication after surgeries using existing ADM grafts. Pre-meshing also prevents the surgeon from having to perform any type or kind of meshing procedures during surgical preparation or during a surgical procedure and ensures an optimal mesh ratio to provide maximum fluid egress, or drainage, from the surgical site to prevent seroma formation and a maximum graft surface area for improved integration into the body post procedure.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Prostheses (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022340544A AU2022340544A1 (en) | 2021-08-30 | 2022-08-30 | Pre-shaped allograft implant for reconstructive surgical use and methods of manufacture and use, and tools for forming a pre-shaped allograft implant for reconstructive surgical use |
KR1020247005801A KR20240046513A (ko) | 2021-08-30 | 2022-08-30 | 재건 수술용 사전성형 동종이식편 임플란트, 그 제조 및 사용 방법, 및 형성용 툴 |
EP22865439.8A EP4366666A1 (fr) | 2021-08-30 | 2022-08-30 | Implant d'allogreffe préformé destiné à être utilisé en chirurgie reconstructrive et procédés de fabrication et d'utilisation, et outils pour former un tel implant |
CA3228022A CA3228022A1 (fr) | 2021-08-30 | 2022-08-30 | Implant d'allogreffe preforme destine a etre utilise en chirurgie reconstructrive et procedes de fabrication et d'utilisation, et outils pour former un tel implant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163238733P | 2021-08-30 | 2021-08-30 | |
US63/238,733 | 2021-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023034313A1 true WO2023034313A1 (fr) | 2023-03-09 |
Family
ID=85413041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/042058 WO2023034313A1 (fr) | 2021-08-30 | 2022-08-30 | Implant d'allogreffe préformé destiné à être utilisé en chirurgie reconstructrive et procédés de fabrication et d'utilisation, et outils pour former un tel implant |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4366666A1 (fr) |
KR (1) | KR20240046513A (fr) |
AU (1) | AU2022340544A1 (fr) |
CA (1) | CA3228022A1 (fr) |
CL (1) | CL2024000456A1 (fr) |
WO (1) | WO2023034313A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3609864A (en) * | 1969-08-27 | 1971-10-05 | Roy C Bassett | Surgical blade handle |
US20120010728A1 (en) * | 2010-07-08 | 2012-01-12 | Lifecell Corporation | Method for shaping tissue matrices |
US20180092737A1 (en) * | 2016-10-03 | 2018-04-05 | Lifecell Corporation | Breast treatment device |
US20200100892A1 (en) * | 2018-10-02 | 2020-04-02 | Tepha, Inc. | Medical devices to limit movement of breast implants |
US20210260245A1 (en) * | 2018-06-22 | 2021-08-26 | Meccellis Biotech | Acellular dermal matrix, in particular for a mammary prosthesis |
-
2022
- 2022-08-30 WO PCT/US2022/042058 patent/WO2023034313A1/fr active Application Filing
- 2022-08-30 KR KR1020247005801A patent/KR20240046513A/ko unknown
- 2022-08-30 AU AU2022340544A patent/AU2022340544A1/en active Pending
- 2022-08-30 CA CA3228022A patent/CA3228022A1/fr active Pending
- 2022-08-30 EP EP22865439.8A patent/EP4366666A1/fr active Pending
-
2024
- 2024-02-14 CL CL2024000456A patent/CL2024000456A1/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3609864A (en) * | 1969-08-27 | 1971-10-05 | Roy C Bassett | Surgical blade handle |
US20120010728A1 (en) * | 2010-07-08 | 2012-01-12 | Lifecell Corporation | Method for shaping tissue matrices |
US20180092737A1 (en) * | 2016-10-03 | 2018-04-05 | Lifecell Corporation | Breast treatment device |
US20210260245A1 (en) * | 2018-06-22 | 2021-08-26 | Meccellis Biotech | Acellular dermal matrix, in particular for a mammary prosthesis |
US20200100892A1 (en) * | 2018-10-02 | 2020-04-02 | Tepha, Inc. | Medical devices to limit movement of breast implants |
Non-Patent Citations (1)
Title |
---|
GILBERT ET AL., DECELLULARIZATION OF TISSUES AND ORGANS, 2006, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pubmed/16519932> |
Also Published As
Publication number | Publication date |
---|---|
CA3228022A1 (fr) | 2023-03-09 |
AU2022340544A1 (en) | 2024-02-15 |
CL2024000456A1 (es) | 2024-06-14 |
KR20240046513A (ko) | 2024-04-09 |
EP4366666A1 (fr) | 2024-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210085443A1 (en) | Pre-shaped allograft implant for reconstructive surgical use and methods of manufacture and use | |
US11642216B2 (en) | Soft tissue repair grafts and processes for preparing and using same | |
US9901440B2 (en) | Breast prosthesis support device based on tissue matrix material, and preparation method therefor | |
US10568914B1 (en) | Human birth tissue laminate and methods of use | |
JP4296405B2 (ja) | 乳房メッシュインプラント | |
US20230114297A1 (en) | Pre-shaped allograft implant for reconstructive surgical use and methods of manufacture and use, and tools for forming a pre-shaped allograft implant for reconstructive surgical use | |
RU2496431C1 (ru) | Способ хирургического лечения туберкулеза легких | |
EP4366666A1 (fr) | Implant d'allogreffe préformé destiné à être utilisé en chirurgie reconstructrive et procédés de fabrication et d'utilisation, et outils pour former un tel implant | |
US20090312843A1 (en) | Tissue Reconstruction Devices and Methods | |
RU2486872C1 (ru) | Способ восстановления нижней стенки глазницы и нижнеглазничного края после травмы | |
US11065094B2 (en) | Biological prosthesis intended for the treatment of parastomal hernias | |
RU2618907C1 (ru) | Способ забора кожного трансплантата и восстановления донорской раны | |
DE GRÓSZ et al. | Scleral buckling with Bioplast® fibrin in retinal detachment | |
RU2737586C1 (ru) | Способ внутрисинусового надпазушного устранения дефектов верхней стенки верхнечелюстного синуса | |
RU93022U1 (ru) | Комбинированный аллотрансплантат для восстановления ушной раковины | |
Gaufin et al. | Use of a Rigid External Bolster for Helical Support During Secondary Intention Healing | |
RU2308914C2 (ru) | Метод фиксации аллопланта к роговице | |
Benhamou et al. | Breast Implants in Cosmetic Surgery: Use of Redon Postsurgery Draining | |
Bames | The Two-Stage Operation for Reduction of Extremely Large Breasts vs. the One-Stage Technique | |
RU2632536C1 (ru) | Способ ушивания раны после операции на тазобедренном суставе | |
Nazar | Evisceration Versus Enucleation in Ocular Globe Injury | |
RU2316268C1 (ru) | Способ подготовки кожно-фасциального лоскута | |
SU1641307A1 (ru) | Способ лечени культи бедра с рубцовоизмененными ткан ми, дефектом мышц | |
RU6514U1 (ru) | Пространственно-объемный аллотрансплантат для опорно-контурной пластики | |
SU1641305A1 (ru) | Способ лечени дефекта большеберцовой кости с дефектом м гких тканей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22865439 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022340544 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3228022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022865439 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022865439 Country of ref document: EP Effective date: 20240207 |
|
ENP | Entry into the national phase |
Ref document number: 2022340544 Country of ref document: AU Date of ref document: 20220830 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20247005801 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |